or Try an Advanced Search...

    Technical Analysis for PALI - Palisade Bio, Inc.

    Grade Last Price % Change Price Change
    F 2.44 0.41% 0.01
    PALI closed up 0.41 percent on Wednesday, November 20, 2024, on 2.57 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PALI trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Shooting Star Candlestick Bearish 0.00%
    Lizard Bearish Bearish Day Trade Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Doji - Bearish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Inside Day Range Contraction 0.41%
    Wide Bands Range Expansion 0.41%
    Outside Day Range Expansion 2.09%
    Wide Bands Range Expansion 2.09%
    Older End-of-Day Signals for PALI ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 16 hours ago
    Reversed from Up about 16 hours ago
    60 Minute Opening Range Breakout about 18 hours ago
    Rose Above Previous Day's High about 18 hours ago
    20 DMA Resistance about 18 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    PALI Chart by TradingView
    Basic chart:

    Profile

    Palisade Bio, Inc. Description

    Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Surgery Abdominal Pain Gastrointestinal Tract Digestive System

    Is PALI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
    Nov 12 Palisade Bio GAAP EPS of -$2.32 beats by $1.03
    Nov 12 Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
    Nov 7 Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
    Oct 31 Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
    Oct 15 Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
    Oct 10 Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
    Oct 8 Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
    Sep 25 Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
    Sep 16 Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
    See more PALI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.35
    52 Week Low 2.18
    Average Volume 99,681
    200-Day Moving Average 4.62
    50-Day Moving Average 3.26
    20-Day Moving Average 2.76
    10-Day Moving Average 2.45
    Average True Range 0.32
    RSI (14) 37.50
    ADX 21.4
    +DI 22.85
    -DI 21.15
    Chandelier Exit (Long, 3 ATRs) 2.95
    Chandelier Exit (Short, 3 ATRs) 3.13
    Upper Bollinger Bands 3.56
    Lower Bollinger Band 1.96
    Percent B (%b) 0.3
    BandWidth 58.02
    MACD Line -0.27
    MACD Signal Line -0.27
    MACD Histogram -0.0049
    Fundamentals Value
    Market Cap 29.6 Million
    Num Shares 12.1 Million
    EPS 0.32
    Price-to-Earnings (P/E) Ratio 7.63
    Price-to-Sales 21.88
    Price-to-Book 0.39
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.25
    Resistance 3 (R3) 3.31 3.10 3.12
    Resistance 2 (R2) 3.10 2.89 3.07 3.07
    Resistance 1 (R1) 2.77 2.77 2.94 2.71 3.02
    Pivot Point 2.56 2.56 2.64 2.53 2.56
    Support 1 (S1) 2.23 2.35 2.40 2.17 1.86
    Support 2 (S2) 2.02 2.23 1.99 1.81
    Support 3 (S3) 1.69 2.02 1.77
    Support 4 (S4) 1.63